OptiBiotix signs first end product application deal in Japan
Anita Riotta
Company News- 3 min read
14:19, 3rd July 2019

OptiBiotix Health’s (OPTI) FOLLOW fully-owned subsidiary ProBiotix Health has signed a non-exclusive license agreement with Tenshindo to use Lactobacillus plantarum, or LPLDL®, in cardiovascular food supplements in Japan.

LPLDL® is set to be the active ingredient in Tenshindo’s cardiovascular health product.

The Japanese partnership opens up a new market for the life sciences company as it continues to focus on compounds designed to tackle obesity, cardiovascular disease and diabetes. 

It also represents the first end product application deal that has emerged from ProBiotix’s agreement with Japanese distributor EIWA Trading Corporation, signed earlier this year, to distribute LPLDL® in the country.

Dr. Luis Gosalbez, Business Development Director of OptiBiotix, commented: "We are pleased to announce this deal with Tenshindo, which will mean our first LPLDL® finished product placement on the Japanese market.

Obtaining an authorised cardiovascular health claim for LPLDL® from Japanese authorities will not only be highly advantageous from the commercial point of view, but also an important endorsement for ProBiotix's science. Tenshindo, with over 30 years of experience in this market, are an excellent commercial and regulatory partner to make the most of this opportunity."

For more news and updates on OptiBiotix Health: FOLLOW

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Login or register to post comments

Recent Articles